BG102999A - Нови 2,3 дизаместени-4(3н)-хиназолинони - Google Patents

Нови 2,3 дизаместени-4(3н)-хиназолинони

Info

Publication number
BG102999A
BG102999A BG102999A BG10299998A BG102999A BG 102999 A BG102999 A BG 102999A BG 102999 A BG102999 A BG 102999A BG 10299998 A BG10299998 A BG 10299998A BG 102999 A BG102999 A BG 102999A
Authority
BG
Bulgaria
Prior art keywords
quinazolinons
diasubstituted
new
neurodegenarativeconditions
diasubstitute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG102999A
Other languages
English (en)
Inventor
Mark Elliott
Willard Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of BG102999A publication Critical patent/BG102999A/bg
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)

Abstract

Изобретението се отнася до нови 2,3-дизаместени-4(3Н)-хиназолинонови съединения с формула до техни фармацевтично приемливи соли и фармацевтични състави и до методи за лечение на невродегенеративни състояния и на такива, свързани с травма на централната нервна система.
BG102999A 1996-05-15 1998-12-08 Нови 2,3 дизаместени-4(3н)-хиназолинони Pending BG102999A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15
PCT/IB1997/000134 WO1997043276A1 (en) 1996-05-15 1997-02-17 Novel 2,3 disubstituted-4(3h)-quinazolinones

Publications (1)

Publication Number Publication Date
BG102999A true BG102999A (bg) 1999-09-30

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102999A Pending BG102999A (bg) 1996-05-15 1998-12-08 Нови 2,3 дизаместени-4(3н)-хиназолинони

Country Status (39)

Country Link
US (1) US6303615B1 (bg)
EP (1) EP0901487B9 (bg)
JP (1) JP3241388B2 (bg)
KR (1) KR100375155B1 (bg)
CN (2) CN1103772C (bg)
AP (1) AP1148A (bg)
AR (1) AR007118A1 (bg)
AT (1) ATE242232T1 (bg)
AU (1) AU730503B2 (bg)
BG (1) BG102999A (bg)
BR (1) BR9709085A (bg)
CA (1) CA2252907C (bg)
CZ (1) CZ295565B6 (bg)
DE (1) DE69722613T2 (bg)
DK (1) DK0901487T3 (bg)
DZ (1) DZ2237A1 (bg)
EA (1) EA002905B1 (bg)
ES (1) ES2198546T3 (bg)
GT (1) GT199700049A (bg)
HK (1) HK1019607A1 (bg)
HN (1) HN1997000052A (bg)
HR (1) HRP970261B1 (bg)
HU (1) HUP9902148A3 (bg)
ID (1) ID17149A (bg)
IL (1) IL126589A (bg)
IS (1) IS4881A (bg)
MA (1) MA26430A1 (bg)
NO (1) NO985293L (bg)
OA (1) OA10918A (bg)
PL (1) PL330042A1 (bg)
PT (1) PT901487E (bg)
SI (1) SI0901487T1 (bg)
SK (1) SK284108B6 (bg)
TN (1) TNSN97087A1 (bg)
TR (1) TR199802296T2 (bg)
TW (1) TW539675B (bg)
WO (1) WO1997043276A1 (bg)
YU (1) YU19197A (bg)
ZA (1) ZA974156B (bg)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001961B1 (ru) 1997-02-28 2001-10-22 Пфайзер Продактс Инк. Атропизомеры 3-гетероарил-4(3н)-хиназолинонов для лечения нейродегенеративных и связанных с травмами цнс состояний
JP2000509731A (ja) * 1997-02-28 2000-08-02 ファイザー・プロダクツ・インク ３−アリール−４（３ｈ）−キナゾリノンのアトロプ異性体およびａｍｐａ受容体アンタゴニストとしてのそれらの使用
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
US6825192B1 (en) 1999-02-15 2004-11-30 Eisai Co., Ltd. Heterodiazinone derivatives
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
TWI409070B (zh) * 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN104211684A (zh) * 2007-09-26 2014-12-17 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
ES2387539T3 (es) 2008-01-30 2012-09-25 Shin Poong Pharmaceutical Co. Ltd. Nuevo derivado de quinazolina-2,4-diona, y composiciones para la profilaxis y tratamiento de enfermedades nerviosas craneales conteniendo el mismo derivado
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
KR20140133590A (ko) 2012-03-05 2014-11-19 길리아드 칼리스토가 엘엘씨 (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
EP3594215A1 (en) 2013-12-20 2020-01-15 Gilead Calistoga LLC Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2019395288A1 (en) 2018-12-14 2021-09-23 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
EP4096661A4 (en) 2020-01-29 2024-03-06 Kamari Pharma Ltd. COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
GB1298603A (en) 1970-04-06 1972-12-06 Karamchand Premchand Private Quinazolinone derivatives
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
NZ266127A (en) 1993-05-06 1997-11-24 Novo Nordisk As Quinoxaline derivatives, preparation and medicaments
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
JP2000509731A (ja) 1997-02-28 2000-08-02 ファイザー・プロダクツ・インク ３−アリール−４（３ｈ）−キナゾリノンのアトロプ異性体およびａｍｐａ受容体アンタゴニストとしてのそれらの使用

Also Published As

Publication number Publication date
AU730503B2 (en) 2001-03-08
EA002905B1 (ru) 2002-10-31
HK1019607A1 (en) 2000-02-18
ATE242232T1 (de) 2003-06-15
US6303615B1 (en) 2001-10-16
DK0901487T3 (da) 2003-08-25
AP9701003A0 (en) 1997-07-31
HN1997000052A (es) 1997-06-26
SK152098A3 (en) 2000-05-16
EP0901487B1 (en) 2003-06-04
AR007118A1 (es) 1999-10-13
ID17149A (id) 1997-12-04
HRP970261B1 (en) 2003-06-30
NO985293L (no) 1999-01-13
CN1420114A (zh) 2003-05-28
HUP9902148A3 (en) 2002-11-28
TW539675B (en) 2003-07-01
MA26430A1 (fr) 2004-12-20
HRP970261A2 (en) 2000-12-31
ZA974156B (en) 1998-11-16
OA10918A (en) 2001-10-25
CZ295565B6 (cs) 2005-08-17
CN1103772C (zh) 2003-03-26
IS4881A (is) 1998-10-27
EP0901487B9 (en) 2004-09-29
DZ2237A1 (fr) 2002-12-03
YU19197A (sh) 1999-09-27
DE69722613T2 (de) 2004-05-13
PT901487E (pt) 2003-08-29
AP1148A (en) 2003-02-28
KR100375155B1 (ko) 2003-08-19
EA199800923A1 (ru) 1999-06-24
IL126589A (en) 2003-06-24
CA2252907A1 (en) 1997-11-20
CA2252907C (en) 2005-05-17
ES2198546T3 (es) 2004-02-01
CN1218464A (zh) 1999-06-02
WO1997043276A1 (en) 1997-11-20
TR199802296T2 (xx) 1999-02-22
GT199700049A (es) 1998-10-21
SI0901487T1 (en) 2003-10-31
JPH11514663A (ja) 1999-12-14
IL126589A0 (en) 1999-08-17
PL330042A1 (en) 1999-04-26
BR9709085A (pt) 1999-08-03
DE69722613D1 (de) 2003-07-10
KR20000011054A (ko) 2000-02-25
JP3241388B2 (ja) 2001-12-25
EP0901487A1 (en) 1999-03-17
AU1554997A (en) 1997-12-05
NO985293D0 (no) 1998-11-13
SK284108B6 (sk) 2004-09-08
TNSN97087A1 (fr) 2005-03-15
HUP9902148A2 (hu) 2000-04-28
CZ352698A3 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
BG102589A (bg) 3-азетидинилалкилпиперидини или - пиролидини катотахикининови антагонисти
FI974640A (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
BG103687A (bg) Атропизомери на 3-хетероарил-4(3н)-хиназолинони за лечение на нервнодегенеративни процеси и състояния, свързани с травми на цнс
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG105962A (bg) Използване на саредутант и неговите фармацевтичноприемливи соли за лечение или предотвратяване на всички разстройства на настроението, разстройства на адаптацията или смесени разстройства безпокойство-депресия
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
GR3021203T3 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane.
BG102667A (bg) Състав, съдържащ диосгенин
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
GR3018814T3 (en) Process for the purification of 1,1,1,2-tetrafluoroethane.
EP0692476A3 (de) Verbessertes Verfahren zur Herstellung von N,N'-Carbonyldiazolen, insbesondere N,N'-Carbonyldiimidazol
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders